These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 29324468)
1. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study. Chan CH; Chan HY; Chen YC Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468 [TBL] [Abstract][Full Text] [Related]
2. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340 [TBL] [Abstract][Full Text] [Related]
5. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII. Mentzel CL; Bakker PR; van Os J; Drukker M; Matroos GE; Hoek HW; Tijssen MA; van Harten PN J Clin Psychiatry; 2017 Mar; 78(3):e279-e285. PubMed ID: 28199071 [TBL] [Abstract][Full Text] [Related]
7. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data. Preskorn SH; Macaluso M J Psychiatr Pract; 2016 Mar; 22(2):117-23. PubMed ID: 27138080 [TBL] [Abstract][Full Text] [Related]
8. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962 [TBL] [Abstract][Full Text] [Related]
9. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T; Perry CM Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633 [TBL] [Abstract][Full Text] [Related]
10. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. Kinon BJ; Kollack-Walker S; Jeste D; Gupta S; Chen L; Case M; Chen J; Stauffer V J Geriatr Psychiatry Neurol; 2015 Mar; 28(1):67-79. PubMed ID: 25009161 [TBL] [Abstract][Full Text] [Related]
11. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V. van Harten PN; Hoek HW; Matroos GE; van Os J J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270 [TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. Miller DD; Eudicone JM; Pikalov A; Kim E J Clin Psychiatry; 2007 Dec; 68(12):1901-6. PubMed ID: 18162021 [TBL] [Abstract][Full Text] [Related]
13. Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study. Hauser RA; Barkay H; Fernandez HH; Jimenez-Shahed J; Factor SA; Gross N; Marinelli L; Gordon MF; Barash S; Finkbeiner S; Chaijale N; Anderson KE J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):386-396. PubMed ID: 38901008 [TBL] [Abstract][Full Text] [Related]
14. Treatment of tardive dyskinesia with donepezil: a pilot study. Caroff SN; Campbell EC; Havey J; Sullivan KA; Mann SC; Gallop R J Clin Psychiatry; 2001 Oct; 62(10):772-5. PubMed ID: 11816865 [TBL] [Abstract][Full Text] [Related]
15. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs]. Seigneurie AS; Sauvanaud F; Limosin F Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134 [TBL] [Abstract][Full Text] [Related]
16. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data. Macaluso M; Flynn A; Preskorn S J Psychiatr Pract; 2016 May; 22(3):203-20. PubMed ID: 27123800 [TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Witter DP; Holbert RC; Suryadevara U Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349 [TBL] [Abstract][Full Text] [Related]
18. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis. Apud JA; Egan MF; Wyatt RJ Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869 [TBL] [Abstract][Full Text] [Related]
19. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. Carbon M; Hsieh CH; Kane JM; Correll CU J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614 [TBL] [Abstract][Full Text] [Related]
20. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Bai YM; Yu SC; Chen JY; Lin CY; Chou P; Lin CC Int Clin Psychopharmacol; 2005 Mar; 20(2):79-85. PubMed ID: 15729082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]